About Nuevolution
Nuevolution is a Healthcare company based in Copenhagen (Denmark) founded in 2001, and was acquired by Amgen in May 2019. Drug treatments for oncology and chronic inflammatory diseases are developed. Nuevolution has raised $12.45 million across 2 funding rounds from investors including Amgen, SEB and Sunstone. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.
Company details
Founded in 2001 and based in Copenhagen, Denmark, drug treatments targeting oncology and chronic inflammatory diseases are developed by the company. Operations focus on biotechnology, utilizing Chemics technology for synthesizing Chemetics molecules that combine drugs, DNA tags, and linkers. High-throughput screening identifies active compounds, followed by optimization from hit identification to lead stages. The domain nuevolution.com supports these activities in the pharmaceutical sector.
- Headquarters Copenhagen, Denmark
- Stage Acquired
- SectorsHealthcare
- Website nuevolution.com
- Social LinkedIn
- Acquired by Amgen (May 2019)
Funding Insights of Nuevolution
Nuevolution has successfully raised a total of $12.45M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $12.45 million completed in June 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.45M
- Total Rounds 2
- Last Round Series B — $12.45M
- Investors Count 5
All 2 funding rounds of Nuevolution with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $12.45M | Series B | – | Industrifonden | |
| Oct 2003 | Series B | – | SLS Venture, Novo Holdings | – |
6 investors in total: 6 institutional.
Investors in Nuevolution
Nuevolution has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, SEB and Sunstone.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Investments in deep-tech, life sciences, and transformative tech are managed. | industrifonden.com | Stockholm, Sweden | ||
| slsventure.com | ||||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
SEB is recognized as a leading Nordic corporate bank. | 1856 | sebgroup.com | Stockholm, Sweden | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Nuevolution
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nuevolution
5 dated milestones of Nuevolution across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Nuevolution is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $12.5M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Amgen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nuevolution
Complete news archive for Nuevolution
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuevolution
Nuevolution was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Nuevolution is headquartered in Copenhagen, Denmark.
Nuevolution is a funded company, having raised a total of $12.45M across 2 funding rounds to date.
Founded in 2001 and based in Copenhagen, Denmark, drug treatments targeting oncology and chronic inflammatory diseases are developed by the company. Operations focus on biotechnology, utilizing Chemics technology for synthesizing Chemetics molecules that combine drugs, DNA tags, and linkers. High-throughput screening identifies active compounds, followed by optimization from hit identification to lead stages. The domain nuevolution.com supports these activities in the pharmaceutical sector.
Nuevolution has 6 investors. Key investors include Amgen, SEB, Sunstone, Industrifonden, and SLS Venture.
Yes. Nuevolution was acquired by Amgen in May 2019.